[Ip-health] USTR Nat. Trade Barriers Report on Thai compulsory licenses

[michael.davis@law.csuohio.edu]

There is no reason for them to do that. It is a classic trap, the kind of
advice you would give to a prisoner at Guantanamo ("Behave and we won't
torture you.") It also smacks too much of the unstated "Trust me," which
is never advice you should take from an adversary.

Mickey Davis

> Why should developing countries reduce their legal flexibility to
> determine royalty rates by such "self regulation"? Is it a realistic
> that opposition to CLs in developing countries would reduce?
>
> bmt
>
> mko wrote:
>> I agree that middle-income countries should explore higher royalty rates
>> on
>> generically-priced drugs sold under a CL.  Doing so wouldn't harm access
>> much; indeed if the higher royalty reduced opposition from USTR & IFPMA,
>> then access could be dramatically improved.  I've tried to model these
>> CL
>> royalties or patent buy-outs from the opportunity cost in R&D from the
>> foregone revenues:
>>
>> http://papers.ssrn.com/sol3/papers.cfm?abstract_id=873402
>>
>> Kevin Outterson
>> Boston University
>>
>>
>> On 4/1/08 9:54 AM, "B.Baker@neu.edu" <B.Baker@neu.edu> wrote:
>>
>>
>>> I think there are four interest facets of the U.S. statement in the
>>> Thai
>>> NTB report (reprinted below).
>>>
>>
> _______________________________________________
> Ip-health mailing list
> Ip-health@lists.essential.org
> http://lists.essential.org/mailman/listinfo/ip-health
>


Mickey Davis
_________________________________
Prof. Michael H. Davis
Professor of Law
Cleveland State Univ. College of Law
1801 Euclid Ave.
Cleveland, OH 44115-2214
(mailing address: 2121 Euclid Ave. LB 234)
216-687-2228
_____________________________________________________________
Patent Attorney Admitted to Practice Before the US Patent and Trademark
Office Reg.No. 45,863